Is Sarepta Therapeutics (SRPT) Using siRNA To Quiet Elevidys Risk Or Redefine Its Pipeline Strategy?

Simply Wall St.01-18

In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2604231129?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-18 00:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604231129","market":"nz","top_or_hot":-1,"title":"Is Sarepta Therapeutics (SRPT) Using siRNA To Quiet Elevidys Risk Or Redefine Its Pipeline Strategy?","media":"Simply Wall St.","content":"<div>\n<p>In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-using-sirna-to-quiet-elevidys-r\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Sarepta Therapeutics (SRPT) Using siRNA To Quiet Elevidys Risk Or Redefine Its Pipeline Strategy?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Sarepta Therapeutics (SRPT) Using siRNA To Quiet Elevidys Risk Or Redefine Its Pipeline Strategy?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-18 00:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-using-sirna-to-quiet-elevidys-r><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-using-sirna-to-quiet-elevidys-r\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-using-sirna-to-quiet-elevidys-r","article_id":"2604231129","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srpt/sarepta-therapeutics/news/is-sarepta-therapeutics-srpt-using-sirna-to-quiet-elevidys-r","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604231129","pubTimestamp":1768667302,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease, expanding its next-generation siRNA platform for neurodegenerative and pulmonary conditions.\nThis move underscores Sarepta’s effort to balance the safety and regulatory setbacks around its gene therapy Elevidys with a broader, modality-diversified rare disease pipeline.\nWe’ll now examine how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","SRPT":"Sarepta Therapeutics","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4139":"生物科技","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4585":"ETF&股票定投概念"},"translate_title":"Sarepta Therapeutics(SRPT)是使用siRNA来降低Elevidys的风险还是重新定义其管道策略？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRPT":1.5},"content_text":"In early January 2026, Sarepta Therapeutics submitted a clinical trial application in New Zealand for INSIGHTT, the first-in-human study of SRP-1005, an siRNA candidate targeting Huntington’s disease, expanding its next-generation siRNA platform for neurodegenerative and pulmonary conditions. This move underscores Sarepta’s effort to balance the safety and regulatory setbacks around its gene therapy Elevidys with a broader, modality-diversified rare disease pipeline. We’ll now examine how Sarepta’s push into siRNA for Huntington’s disease reshapes the existing investment narrative around Elevidys-related risks. Find companies with promising cash flow potential yet trading below their fair value.AdvertisementSarepta Therapeutics Investment Narrative RecapTo own Sarepta today, you need to believe its rare disease franchise can weather Elevidys’ safety and regulatory headwinds while a broader RNA and gene therapy pipeline supports future cash flows. The new INSIGHTT filing for SRP-1005 expands the siRNA platform but does not materially change that near term Elevidys safety and label clarity remain the key catalyst and the biggest risk to the business. The most relevant recent update alongside INSIGHTT is Sarepta’s preliminary 2025 revenue, with US$1.86 billion in net product sales and US$898.7 million from Elevidys. This underscores how dependent the story still is on stabilizing Elevidys’ commercial and regulatory trajectory, even as the siRNA programs try to broaden the company’s long term opportunity set. Yet even as Sarepta expands into siRNA, investors should be aware of the lingering Elevidys liver safety concerns and FDA oversight... Read the full narrative on Sarepta Therapeutics (it's free!)Sarepta Therapeutics' narrative projects $1.4 billion revenue and $171.6 million earnings by 2028. This requires a 17.0% yearly revenue decline and a $229.6 million earnings increase from -$58.0 million today.Uncover how Sarepta Therapeutics' forecasts yield a $20.61 fair value, in line with its current price.Exploring Other PerspectivesSRPT 1-Year Stock Price Chart Ten fair value estimates from the Simply Wall St Community span roughly US$20.61 to US$168.51, showing just how far apart individual views can be. When you set that against Elevidys’ ongoing safety scrutiny and regulatory risk, it becomes clear why you should compare several viewpoints before forming an opinion on Sarepta’s prospects.Explore 10 other fair value estimates on Sarepta Therapeutics - why the stock might be worth over 7x more than the current price!Build Your Own Sarepta Therapeutics NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Sarepta Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Sarepta Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sarepta Therapeutics' overall financial health at a glance.Looking For Alternative Opportunities?Our top stock finds are flying under the radar-for now. Get in early:These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2604231129","isCrawlerRequest":true}